Drug intelligence / Profile preview

MTDX-301

Development stage: Preclinical
Lead developer: Montdorex
Modality: Small Molecules

Overview

MTDX-301 is a small molecule drug developed by Montdorex. It acts as an endo-exonuclease (EE) inhibitor, targeting the EE enzyme class. The primary therapeutic area under investigation for MTDX-301 is neoplasms (cancers). As of March 2025, its highest development status is preclinical, and there are no reported clinical trials or approvals for this compound.

Beyond the preview

Go deeper on MTDX-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTDX-301.

Explore the full profile